A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

The current study aimed to evaluate the safety profile and efficacy of a cannabis-based sublingual spray, CBDEX10(®) (containing 100 µg cannabidiol and 10 µg Δ(9)-tetrahydrocannabinol per puff; CBD/Δ(9)-THC 10:1), in improving lipid profile and glycemic state of the diabetic patients. Fifty diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Afshar, Shima, Khalili, Shayesteh, Amin, Gholamreza, Abbasinazari, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Brieflands 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024807/
https://www.ncbi.nlm.nih.gov/pubmed/36945340
http://dx.doi.org/10.5812/ijpr-132647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024807/
https://www.ncbi.nlm.nih.gov/pubmed/36945340
http://dx.doi.org/10.5812/ijpr-132647

Ejemplares similares